Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives | 1596 | 13010-47-4 |
None
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.02 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 4, 1976 | FDA | CORDEN PHARMA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Tumour pseudoprogression | 63.65 | 33.15 | 10 | 1389 | 220 | 50603505 |
Platelet count decreased | 61.92 | 33.15 | 37 | 1362 | 100689 | 50503036 |
Ototoxicity | 53.61 | 33.15 | 11 | 1388 | 1116 | 50602609 |
Full blood count abnormal | 46.00 | 33.15 | 19 | 1380 | 23369 | 50580356 |
Geotrichum infection | 43.42 | 33.15 | 8 | 1391 | 462 | 50603263 |
Mucosal inflammation | 42 | 33.15 | 21 | 1378 | 40121 | 50563604 |
Nausea | 37.30 | 33.15 | 68 | 1331 | 705330 | 49898395 |
Thrombocytopenia | 35.84 | 33.15 | 29 | 1370 | 127644 | 50476081 |
Disease progression | 33.94 | 33.15 | 25 | 1374 | 95841 | 50507884 |
Death | 33.69 | 33.15 | 43 | 1356 | 325336 | 50278389 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Disease progression | 59.51 | 30.10 | 47 | 1951 | 81869 | 29490660 |
Aeromonas infection | 53.60 | 30.10 | 10 | 1988 | 247 | 29572282 |
Second primary malignancy | 45.15 | 30.10 | 17 | 1981 | 6688 | 29565841 |
Nausea | 39.51 | 30.10 | 70 | 1928 | 289185 | 29283344 |
Tumour pseudoprogression | 32.37 | 30.10 | 7 | 1991 | 369 | 29572160 |
Platelet count decreased | 31.53 | 30.10 | 37 | 1961 | 104635 | 29467894 |
Fatigue | 31.39 | 30.10 | 67 | 1931 | 316754 | 29255775 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Tumour pseudoprogression | 95.55 | 29.04 | 17 | 2877 | 490 | 64495348 |
Disease progression | 81.55 | 29.04 | 60 | 2834 | 141620 | 64354218 |
Platelet count decreased | 58.34 | 29.04 | 53 | 2841 | 167658 | 64328180 |
Aeromonas infection | 54.86 | 29.04 | 10 | 2884 | 331 | 64495507 |
Acute myeloid leukaemia | 51.58 | 29.04 | 25 | 2869 | 27438 | 64468400 |
Geotrichum infection | 50.52 | 29.04 | 11 | 2883 | 907 | 64494931 |
Seizure | 48.95 | 29.04 | 48 | 2846 | 166844 | 64328994 |
Second primary malignancy | 45.28 | 29.04 | 18 | 2876 | 12319 | 64483519 |
Ototoxicity | 43.19 | 29.04 | 12 | 2882 | 2711 | 64493127 |
Off label use | 36.05 | 29.04 | 84 | 2810 | 632722 | 63863116 |
Death | 35.38 | 29.04 | 71 | 2823 | 482634 | 64013204 |
Thrombocytopenia | 34.27 | 29.04 | 46 | 2848 | 223755 | 64272083 |
Malignant neoplasm progression | 34.05 | 29.04 | 33 | 2861 | 112838 | 64383000 |
None
Source | Code | Description |
---|---|---|
ATC | L01AD02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrosoureas |
FDA MoA | N0000000236 | Alkylating Activity |
FDA EPC | N0000175558 | Alkylating Drug |
MeSH PA | D000477 | Alkylating Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
MeSH PA | D009676 | Noxae |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hodgkin's disease | indication | 118599009 | |
Neoplasm of brain | indication | 126952004 | DOID:1319 |
Allogeneic bone marrow transplantation | off-label use | 58390007 | |
Mycosis | contraindication | 3218000 | DOID:1564 |
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Viral disease | contraindication | 34014006 | DOID:934 |
Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Bacterial infectious disease | contraindication | 87628006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Bleeding | contraindication | 131148009 | |
Liver function tests abnormal | contraindication | 166603001 | |
Drug-induced hepatitis | contraindication | 235876009 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Pulmonary Infiltrates | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.87 | acidic |
None
None
None
ID | Source |
---|---|
4018138 | VUID |
N0000146475 | NUI |
D00363 | KEGG_DRUG |
4018138 | VANDF |
C0023972 | UMLSCUI |
CHEBI:6520 | CHEBI |
CHEMBL514 | ChEMBL_ID |
DB01206 | DRUGBANK_ID |
D008130 | MESH_DESCRIPTOR_UI |
3950 | PUBCHEM_CID |
3184 | INN_ID |
7214 | IUPHAR_LIGAND_ID |
7BRF0Z81KG | UNII |
6466 | RXNORM |
4991 | MMSL |
52513 | MMSL |
d01341 | MMSL |
002639 | NDDF |
387227009 | SNOMEDCT_US |
40999006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Gleostine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58181-3040 | CAPSULE, GELATIN COATED | 10 mg | ORAL | NDA | 24 sections |
Gleostine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58181-3041 | CAPSULE, GELATIN COATED | 40 mg | ORAL | NDA | 24 sections |
Gleostine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58181-3042 | CAPSULE, GELATIN COATED | 100 mg | ORAL | NDA | 24 sections |